- |||||||||| zuclomiphene (VERU-944) / Veru Inc, WP1066 / Moleculin, WPD Pharma
Biomarker, Journal: Experimental verification and validation of immune biomarkers based on chromatin regulators in ischemic stroke. (Pubmed Central) - Sep 20, 2022
Molecular docking simulations revealed that mevastatin, WP1066, cladribine, trichostatin A, mequitazine, and zuclomiphene may be potential immunomodulatory drugs for IS. Overall, the results of this study contribute to the identification of CR-related immune therapeutics target in IS and provide an important reference for further research.
- |||||||||| zuclomiphene (VERU-944) / Veru Inc
Trial completion, Metastases: Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer (clinicaltrials.gov) - Dec 3, 2020
P2, N=93, Completed,
Overall, the results of this study contribute to the identification of CR-related immune therapeutics target in IS and provide an important reference for further research. Active, not recruiting --> Completed
- |||||||||| Androxal (enclomifene) / Repros
Journal: Enclomiphene citrate: A treatment that maintains fertility in men with secondary hypogonadism. (Pubmed Central) - May 29, 2020
Initial studies demonstrated that enclomiphene maintains the androgenic benefit of clomiphene citrate without the undesirable effects attributable to zuclomiphene. This article reviews the difficulties associated with the FDA approval of a new molecular entity related to the treatment of hypogonadism.
- |||||||||| zuclomiphene (VERU-944) / Veru Inc
Trial completion date, Metastases: Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer (clinicaltrials.gov) - May 19, 2020
P2, N=120, Active, not recruiting,
This article reviews the difficulties associated with the FDA approval of a new molecular entity related to the treatment of hypogonadism. Trial completion date: Apr 2020 --> Jul 2020
- |||||||||| zuclomiphene (VERU-944) / Veru Inc
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer (clinicaltrials.gov) - Jan 22, 2020
P2, N=120, Active, not recruiting,
Trial completion date: Apr 2020 --> Jul 2020 Trial completion date: Jul 2020 --> Apr 2020 | Trial primary completion date: Jul 2020 --> Apr 2020 | Recruiting --> Active, not recruiting
- |||||||||| zuclomiphene (VERU-944) / Veru Inc
Enrollment open, Trial completion date, Trial primary completion date, Metastases: Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer (clinicaltrials.gov) - Jan 2, 2020
P2, N=120, Recruiting,
Trial completion date: Jul 2020 --> Apr 2020 | Trial primary completion date: Jul 2020 --> Apr 2020 | Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting | Trial completion date: Feb 2020 --> Jul 2020 | Trial primary completion date: Feb 2020 --> Jul 2020
- |||||||||| zuclomiphene (VERU-944) / Veru Inc, Androxal (enclomifene) / Repros
Journal: HPT-Axis Effects and Urinary Detection Following Clomiphene Administration in Males. (Pubmed Central) - Dec 21, 2019
Clomiphene significantly raises serum testosterone and gonadotropins in healthy men and thus can be abused as a performance-enhancing drug. Such abuse is detectable in urine for four months or greater following short-term use.
|
